Medical Week Daily

Medical news today: Saturday, November 14, 2026

FDA approves a weekly self-injected myasthenia gravis drug; US measles deaths rise; India enforces lower cancer-drug prices

Get tomorrow's issue in your inbox.

  1. 01

    US states report two more measles deaths as national cases top 5,400

    Source: MedPage Today

    Wisconsin and Pennsylvania each reported a measles-associated death on Friday, bringing deaths recorded by state health departments this year to 10. The CDC had confirmed 5,412 US cases as of November 12, 97% in unvaccinated people, and MedPage reports the Pan American Health Organization (PAHO) is expected to decide imminently whether the US loses its measles elimination status.

    Why it mattersOutbreaks cost families lost school and work days and cost health systems money for tracing and hospital care; MedPage notes the CDC reported 92.4% MMR coverage for 2025-26 kindergarteners, below the 95% level it cites for herd immunity. More on Drug & device safety →

  2. 02

    WHO committee says international poliovirus spread remains a public-health emergency

    Source: World Health Organization

    WHO published the statement of its 46th International Health Regulations Emergency Committee meeting on November 13. Since the previous meeting in May, 25 new wild poliovirus type 1 cases were reported from Afghanistan (22) and Pakistan (3), bringing 2026 reports to 29 (25 in Afghanistan and 4 in Pakistan). The committee concluded that the risk of international spread remains a Public Health Emergency of International Concern and recommended extending temporary recommendations for a further three months. It separately concluded that the event does not constitute a pandemic emergency. WHO also reported 155 circulating vaccine-derived poliovirus cases and 61 environmental detections across 20 countries in 2026 as of September 15.

    Why it mattersThis is an IHR risk determination, not a declaration of a pandemic emergency. It highlights continuing cross-border WPV1 transmission and immunisation gaps in Afghanistan and Pakistan; the cVDPV figures have a September 15 data cutoff and should not be presented as a November real-time count. More on Approvals & regulatory →

  3. 03

    EMA recommends extending obinutuzumab (Gazyvaro) to adults with active systemic lupus erythematosus

    Source: European Medicines Agency

    EMA said on November 13 that its human medicines committee recommended extending Gazyvaro (obinutuzumab) as add-on treatment for adults with moderate-to-severe active systemic lupus erythematosus who meet the specified antibody and treatment-response criteria. In a randomised, double-blind study of 303 adults, 76.7% of patients receiving obinutuzumab plus standard treatment achieved an SRI4 response at 52 weeks, compared with 53.5% receiving placebo plus standard treatment. EMA lists upper respiratory and urinary tract infections among the most frequently reported side effects in the SLE study. The committee opinion is an intermediate regulatory step; the European Commission must still decide on the marketing-authorisation extension.

    Why it mattersThis is a positive CHMP recommendation, not yet an EU-wide authorisation for the new indication. The trial supports further consideration of B-cell depletion in active SLE, while infection events remain relevant to benefit-risk assessment and safety monitoring. More on Approvals & regulatory →

  4. 04

    FDA approves gefurulimab, a once-weekly self-injected drug for generalized myasthenia gravis

    Source: MedPage Today

    The FDA approved gefurulimab (Klygefa), a nanobody (a small antibody fragment) that blocks the complement protein C5, for adults with anti-acetylcholine-receptor antibody-positive generalized myasthenia gravis, an autoimmune disease that causes muscle weakness. In the 260-patient phase 3 PREVAIL trial, it improved daily-activity scores versus placebo; it carries a boxed warning for serious meningococcal infections and is available only through a REMS (restricted safety) program.

    Why it mattersIt is the fourth C5 inhibitor approved for this condition and is self-administered under the skin once a week; more competition in a costly drug class is something insurers and patients will watch when prices are set. More on Approvals & regulatory →

  5. 05

    US delays enforcement of Medicaid work requirements by six months, to July 1, 2027

    Source: STAT

    The Trump administration said Friday it is giving states six more months to start enforcing Medicaid work requirements, which require many working-age enrollees without dependent children to work, study or volunteer at least 80 hours a month unless exempt. STAT reports a federal judge recently rejected the government's 'medically frail' definition. (STAT+, paywall)

    Why it mattersLow-income adults in Medicaid-expansion states keep their current coverage rules for longer, which delays the risk of losing insurance over paperwork and gives families more time to document work or exemptions.

  6. 06

    Cosmetics: CeraVe signs its first film tie-up as 'official moisturiser of Arrakis' for Dune Part Three

    Source: Cosmetics Business

    L'Oréal-owned CeraVe launched a global campaign around its moisturising cream tied to Dune Part Three, ahead of the film's December release; the series of social films debuted on November 13. CeraVe's global brand president told Cosmetics Business it is the brand's first film partnership.

    Why it mattersBig entertainment tie-ups add marketing cost to everyday skincare; shoppers can compare ingredients and price per gram rather than the campaign when choosing a moisturiser. More on Cosmetics & skincare →

  7. 07

    India's price regulator orders strict compliance with lower prices for 137 cancer drugs

    Source: The Hindu BusinessLine

    The National Pharmaceutical Pricing Authority (NPPA) told manufacturers, retailers and hospitals to follow revised maximum retail prices (MRPs) for 137 non-scheduled anti-cancer drugs, which took effect on November 9. Sellers must display the revised price lists, and violations can trigger overcharging proceedings under the Drugs (Prices Control) Order, 2013.

    Why it mattersPatients and caregivers in India can check that they are charged the revised MRP and report overcharging through the Pharma Sahi Daam app, the helpline 1800-111-255 or monitoring-nppa@gov.in. More on Approvals & regulatory →

  8. 08

    Novo files sickle cell drug etavopivat for approval in the US and Europe

    Source: BioPharma Dive

    Markets: Novo filed US and European approval applications on Friday for etavopivat, which it acquired through its roughly $1 billion 2022 buyout of Forma Therapeutics; BioPharma Dive reports the drug reduced pain crises by 27% over a year in testing and that Novo sees it as a future blockbuster. The same roundup reports that Addex spin-out Neurosterix raised $105 million in a Series B round.

    Why it mattersA regulatory decision on etavopivat becomes a revenue milestone investors will track for Novo, and for people with sickle cell disease it could add a new treatment option if approved. Not investment advice. More on Approvals & regulatory →

    Market news · Not investment advice

  9. 09

    e.l.f. Beauty commits to 50% clean electricity across manufacturing suppliers by 2032

    Source: Cosmetics Business

    e.l.f. Beauty's latest impact report says it aims for 50% clean electricity across its manufacturing suppliers by March 2032, up from 14% in 2026 and 2% in 2023. The company also said it partnered with the non-profit Rivet in the UK and India on a youth initiative.

    Why it mattersSustainability pledges are company-reported targets, not product claims; for shoppers and investors they are a commitment to track against future impact reports. More on Markets →

    Market news · Not investment advice

  10. 10

    EMA committee recommends seven new medicines, including two insulin aspart biosimilars

    Source: EMA

    The EMA's human medicines committee (CHMP) recommended seven medicines for EU approval at its November meeting, including Baxfendy (baxdrostat) for hard-to-control high blood pressure, two lung cancer drugs, two insulin aspart biosimilars (Garzulys and Donrafylix), and generic fondaparinux and ruxolitinib. It also backed new uses for 11 medicines, including Gazyvaro (obinutuzumab) for lupus.

    Why it mattersBiosimilars (close copies of biologic medicines) and generics usually add price competition, which can lower what health systems and patients pay for insulin and other drugs once they are launched. More on Approvals & regulatory →

  11. 11

    Medline expands repair, replace and refund options in its recall of all Medline Brand beds

    Source: FDA

    Medline, which recalled all Medline Brand beds, rails, mattresses and accessories sold in the US and Canada on October 14 over a potential fire hazard and entrapment risk, says it has received reports of seven deaths and 35 serious injuries as of November 8. The company-posted notice sets out interim use instructions and says repair, replacement or a full or partial refund may be available for some products bought in the last five years.

    Why it mattersFamilies and care homes with these beds should check eligibility with their supplier (or Medline at 1-800-950-0128, option 7) to get a repair, replacement or refund rather than paying for a new bed themselves. More on Drug & device safety →

  12. 12

    Supplements: Shiseido launches a beauty-from-within drink-and-jelly set as Danone opens a Shanghai gut-health lab

    Source: NutraIngredients

    NutraIngredients' weekly roundup reports that Shiseido launched a set combining its bestselling functional drink with a new jelly stick after a company survey of 207 women, and that Danone opened a research centre in Shanghai with a 900 m² microbiome lab. Australian brand eimele launched an app to work with content creators across Asia-Pacific.

    Why it mattersBeauty-from-within and gut-health products are growing categories in Asia; these are company launches and surveys, not evidence of health benefits, so compare cost against what the label actually claims. More on Approvals & regulatory →

  13. 13

    WHO members make progress on pathogen access and benefit-sharing annex, targeting May 2027

    Source: World Health Organization

    After two weeks of negotiations, WHO said member states had advanced discussions on the Pathogen Access and Benefit-Sharing (PABS) Annex to the WHO Pandemic Agreement. The work covers sharing pathogens with pandemic potential and genetic sequence data, alongside equitable access to resulting vaccines, diagnostics and therapeutics. States reaffirmed the goal of finalising the annex for consideration by the World Health Assembly in May 2027; formal negotiations are scheduled to resume in January 2027, with further rounds in February and March. The annex has not yet been finalised.

    Why it mattersThe framework could shape how pathogen samples and sequence information are shared and how benefits from resulting medical products are distributed during future health emergencies. For regulatory and PV stakeholders, this is policy development rather than a new operational requirement: key terms and mechanisms remain under negotiation. More on Approvals & regulatory →

  14. 14

    Survey finds 11% of working-age US adults now lack health insurance

    Source: JAMA

    JAMA reports on a 2026 Commonwealth Fund survey of more than 7,300 working-age adults: about 11% of people aged 19 to 64 are uninsured, significantly more than in 2024, and Medicaid enrollment fell from 16% in 2022 to 13% in 2026. Half of those surveyed said they delayed or avoided care because of cost.

    Why it mattersLosing coverage shifts medical bills straight onto households; the survey says these declines came before further Medicaid and marketplace changes slated for 2028. More on Journal papers →

  15. 15

    Merck and Moderna's personalized mRNA vaccine cuts melanoma recurrence risk in phase 3

    Source: JAMA

    In the INTerpath-001 trial of about 1,100 patients with surgically removed stage IIB-IV melanoma, adding intismeran autogene (a vaccine made from each patient's own tumour) to pembrolizumab (Keytruda) gave a 2-year recurrence-free survival rate of 82% versus 70% with pembrolizumab alone, according to results the companies announced at a conference. The most common side effects were fever, injection-site pain and fatigue.

    Why it mattersIf regulators approve it, a made-to-order cancer vaccine would raise new questions about cost and insurance coverage; the trial is ongoing and results are company-announced. More on Approvals & regulatory →

New here? How to read this digest
Each story links to its original source. "Why it matters" explains what it means for you in plain language. This is news, not medical advice: talk to your doctor about your own care. Browse all topics or the archive.

More recent digests

Free daily email

The day's approvals, safety signals and trials, in five minutes.

Join the list with just your email. You can also follow the RSS feed.

Free, one field, no spam. We only use your address to send Medical Week Daily and never sell it. Ask to be removed any time via the contact page. See the privacy note.

For information and education only. Not medical advice. Medical Week Daily summarizes published health news in plain language for general readers. It does not replace advice from your doctor, product labeling or regulatory documents. Always consult a qualified healthcare professional about your own care, and check the original source. Full medical disclaimer